Bavarian Nordic has initiated two Phase III clinical trials of its mpox vaccine, Jynneos, in pregnant and breastfeeding women ...

Clinical trials of Jynneos have begun or will begin soon in infants and children 2 years old and younger, and in pregnant or ...

COPENHAGEN, Denmark I June 26, 2025 I Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of the first of two clinical trials designed to support ...

First studies to evaluate MVA-BN in infants under 2 years of age and pregnant and breastfeeding women.The multi-partner research project is aimed at expanding access to mpox vaccines for vulnerable ...

The FDA approval of Vimkunya has given the chikungunya vaccine’s owner, Bavarian Nordic, an extra financial windfall. | The ...

Danish vaccine specialist Bavarian Nordic (OMX: BAVA) is set to collect $160 million from the sale of a US priority review ...

Sale prices for the vouchers – which slash FDA review times for a drug – have increased in the past year as biotech funding ...

Bavarian Nordic has commenced a Phase III trial of its chikungunya vaccine, CHIKV VLP, targeting the paediatric population aged two to 11 years old. This marks the first study of the single-dose, ...

Bavarian Nordic’s Q3 2024 financial performance was characterized by strong growth in its Travel Health segment, which helped offset declines in Public Preparedness.